Please enable JavaScript to continue using this application.

Compare $EBS vs $ZNTL | Chartloom

Compare

$EBS vs $ZNTL

Emergent BioSolutions Inc · Zentalis Pharmaceuticals Inc

EBS

Emergent BioSolutions Inc

ZNTL

Zentalis Pharmaceuticals Inc

Compare $EBS vs $ZNTL

Comparing Emergent BioSolutions Inc and Zentalis Pharmaceuticals Inc

EBSEmergent BioSolutions Inc

ZNTLZentalis Pharmaceuticals Inc

EBSEmergent BioSolutions Inc

Market cap

$364M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-9.6%

YTD performance

-43.6%

52W performance

-28.6%

FCF yield

9.7%

ZNTLZentalis Pharmaceuticals Inc

Market cap

$188M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

92.7%

52W performance

61.0%

FCF yield

-68.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EBS

ZNTL

Detailed metrics comparison

EBS

Emergent BioSolutions Inc

ZNTL

Zentalis Pharmaceuticals Inc

Market Cap

EBS$364M

ZNTL$188M

Enterprise Value

EBS$806M

ZNTL$163M

Price

EBS$7.06

ZNTL$2.64

P/E Ratio

EBSN/A

ZNTLN/A

P/S Ratio

EBS0.47x

ZNTL0.00x

EV/Sales

EBS1.05x

ZNTL0.00x

EV/EBITDA

EBS3.65x

ZNTL0.00x

P/B Ratio

EBS0.95x

ZNTL1.70x

P/FCF Ratio

EBS10.26x

ZNTLN/A

EV/FCF

EBS22.72x

ZNTL-1.27x

PEG Ratio

EBSN/A

ZNTLN/A

Forward P/E (NTM)

EBSN/A

ZNTLN/A

Forward P/S (NTM)

EBSN/A

ZNTLN/A

Revenue (TTM)

EBS$770M

ZNTL$0

Revenue Growth (YoY)

EBS-9.6%

ZNTLN/A

Forward Rev Growth

EBS7.1%

ZNTL447.5%

Gross Margin (TTM)

EBS55.8%

ZNTL0.0%

Operating Margin (TTM)

EBS0.0%

ZNTL0.0%

EBITDA Margin (TTM)

EBS28.7%

ZNTL0.0%

Net Margin (TTM)

EBS-23.0%

ZNTL0.0%

FCF Margin (TTM)

EBS4.6%

ZNTLN/A

Net Income (TTM)

EBS$-177M

ZNTL$-62M

FCF (TTM)

EBS$36M

ZNTL$-128M

EPS (TTM)

EBS-$3.43

ZNTL$0.00

ROE (TTM)

EBS-3591.0%

ZNTL-5277.0%

ROA (TTM)

EBS-1356.0%

ZNTL-4055.0%

ROIC (TTM)

EBS-1622.0%

ZNTL-5277.0%

Cash

EBS$140M

ZNTL$25M

Debt

EBS$582M

ZNTL$0

Net Cash/Debt

EBS$-442M

ZNTL$25M

Current Ratio (TTM)

EBS5.42x

ZNTL4.82x

Quick Ratio (TTM)

EBS2.74x

ZNTL4.64x

Debt/Equity (TTM)

EBS1.70x

ZNTL0.00x

Debt/Assets (TTM)

EBS0.0%

ZNTL0.0%

Interest Coverage (TTM)

EBSN/A

ZNTLN/A

Net Debt/EBITDA (TTM)

EBS0.00x

ZNTL0.00x

Beta

EBS2.42

ZNTL1.92

52W Performance

EBS-28.6%

ZNTL61.0%

YTD Performance

EBS-43.6%

ZNTL92.7%

% from 52W High

EBS-49.8%

ZNTL-62.0%

% from 52W Low

EBS61.9%

ZNTL117.8%

Asset Turnover (TTM)

EBS0.59x

ZNTL0.00x

FCF Yield (TTM)

EBS9.7%

ZNTL-68.2%

Earnings Yield (TTM)

EBS-48.5%

ZNTL-32.9%

Dividend Yield (TTM)

EBSN/A

ZNTLN/A

Rule of 40

EBS-4.9

ZNTL0.0

EV/GP/RG

EBS0.27

ZNTLN/A

Ticker research

View EBS research View ZNTL research

Metric	EBS Emergent BioSolutions Inc	ZNTL Zentalis Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$188M
Enterprise Value	$806M	$163M
Price	$7.06	$2.64
P/E Ratio	N/A	N/A
P/S Ratio	0.47x	0.00x
EV/Sales	1.05x	0.00x
EV/EBITDA	3.65x	0.00x
P/B Ratio	0.95x	1.70x
P/FCF Ratio	10.26x	N/A
EV/FCF	22.72x	-1.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$770M	$0
Revenue Growth (YoY)	-9.6%	N/A
Forward Rev Growth	7.1%	447.5%
Profitability
Gross Margin (TTM)	55.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	28.7%	0.0%
Net Margin (TTM)	-23.0%	0.0%
FCF Margin (TTM)	4.6%	N/A
Net Income (TTM)	$-177M	$-62M
FCF (TTM)	$36M	$-128M
EPS (TTM)	-$3.43	$0.00
ROE (TTM)	-3591.0%	-5277.0%
ROA (TTM)	-1356.0%	-4055.0%
ROIC (TTM)	-1622.0%	-5277.0%
Financial Health
Cash	$140M	$25M
Debt	$582M	$0
Net Cash/Debt	$-442M	$25M
Current Ratio (TTM)	5.42x	4.82x
Quick Ratio (TTM)	2.74x	4.64x
Debt/Equity (TTM)	1.70x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.42	1.92
52W Performance	-28.6%	61.0%
YTD Performance	-43.6%	92.7%
% from 52W High	-49.8%	-62.0%
% from 52W Low	61.9%	117.8%
Efficiency & Yields
Asset Turnover (TTM)	0.59x	0.00x
FCF Yield (TTM)	9.7%	-68.2%
Earnings Yield (TTM)	-48.5%	-32.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	0.0
EV/GP/RG	0.27	N/A
Ticker research	View EBS research	View ZNTL research

Valuation

P/S Ratio

ZNTL

0.00x

EBS

0.47x

EV/FCF

ZNTL

-1.27x

EBS

22.72x

Growth & revenue

Revenue Growth TTM

EBS

-9.6%

Forward Revenue Growth

ZNTL

447.5%

EBS

7.1%

Profitability & performance

Gross Margin

EBS

55.8%

ZNTL

0.0%

ROE

EBS

-3591.0%

ZNTL

-5277.0%

FCF Yield %

EBS

9.7%

ZNTL

-68.2%

52-Week Performance

ZNTL

61.0%

EBS

-28.6%

Detailed metrics comparison

EBS

Emergent BioSolutions Inc

ZNTL

Zentalis Pharmaceuticals Inc

Market Cap

EBS$364M

ZNTL$188M

Enterprise Value

EBS$806M

ZNTL$163M

Price

EBS$7.06

ZNTL$2.64

P/E Ratio

EBSN/A

ZNTLN/A

P/S Ratio

EBS0.47x

ZNTL0.00x

EV/Sales

EBS1.05x

ZNTL0.00x

EV/EBITDA

EBS3.65x

ZNTL0.00x

P/B Ratio

EBS0.95x

ZNTL1.70x

P/FCF Ratio

EBS10.26x

ZNTLN/A

EV/FCF

EBS22.72x

ZNTL-1.27x

PEG Ratio

EBSN/A

ZNTLN/A

Forward P/E (NTM)

EBSN/A

ZNTLN/A

Forward P/S (NTM)

EBSN/A

ZNTLN/A

Revenue (TTM)

EBS$770M

ZNTL$0

Revenue Growth (YoY)

EBS-9.6%

ZNTLN/A

Forward Rev Growth

EBS7.1%

ZNTL447.5%

Gross Margin (TTM)

EBS55.8%

ZNTL0.0%

Operating Margin (TTM)

EBS0.0%

ZNTL0.0%

EBITDA Margin (TTM)

EBS28.7%

ZNTL0.0%

Net Margin (TTM)

EBS-23.0%

ZNTL0.0%

FCF Margin (TTM)

EBS4.6%

ZNTLN/A

Net Income (TTM)

EBS$-177M

ZNTL$-62M

FCF (TTM)

EBS$36M

ZNTL$-128M

EPS (TTM)

EBS-$3.43

ZNTL$0.00

ROE (TTM)

EBS-3591.0%

ZNTL-5277.0%

ROA (TTM)

EBS-1356.0%

ZNTL-4055.0%

ROIC (TTM)

EBS-1622.0%

ZNTL-5277.0%

Cash

EBS$140M

ZNTL$25M

Debt

EBS$582M

ZNTL$0

Net Cash/Debt

EBS$-442M

ZNTL$25M

Current Ratio (TTM)

EBS5.42x

ZNTL4.82x

Quick Ratio (TTM)

EBS2.74x

ZNTL4.64x

Debt/Equity (TTM)

EBS1.70x

ZNTL0.00x

Debt/Assets (TTM)

EBS0.0%

ZNTL0.0%

Interest Coverage (TTM)

EBSN/A

ZNTLN/A

Net Debt/EBITDA (TTM)

EBS0.00x

ZNTL0.00x

Beta

EBS2.42

ZNTL1.92

52W Performance

EBS-28.6%

ZNTL61.0%

YTD Performance

EBS-43.6%

ZNTL92.7%

% from 52W High

EBS-49.8%

ZNTL-62.0%

% from 52W Low

EBS61.9%

ZNTL117.8%

Asset Turnover (TTM)

EBS0.59x

ZNTL0.00x

FCF Yield (TTM)

EBS9.7%

ZNTL-68.2%

Earnings Yield (TTM)

EBS-48.5%

ZNTL-32.9%

Dividend Yield (TTM)

EBSN/A

ZNTLN/A

Rule of 40

EBS-4.9

ZNTL0.0

EV/GP/RG

EBS0.27

ZNTLN/A

Ticker research

View EBS research View ZNTL research

Metric	EBS Emergent BioSolutions Inc	ZNTL Zentalis Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$188M
Enterprise Value	$806M	$163M
Price	$7.06	$2.64
P/E Ratio	N/A	N/A
P/S Ratio	0.47x	0.00x
EV/Sales	1.05x	0.00x
EV/EBITDA	3.65x	0.00x
P/B Ratio	0.95x	1.70x
P/FCF Ratio	10.26x	N/A
EV/FCF	22.72x	-1.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$770M	$0
Revenue Growth (YoY)	-9.6%	N/A
Forward Rev Growth	7.1%	447.5%
Profitability
Gross Margin (TTM)	55.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	28.7%	0.0%
Net Margin (TTM)	-23.0%	0.0%
FCF Margin (TTM)	4.6%	N/A
Net Income (TTM)	$-177M	$-62M
FCF (TTM)	$36M	$-128M
EPS (TTM)	-$3.43	$0.00
ROE (TTM)	-3591.0%	-5277.0%
ROA (TTM)	-1356.0%	-4055.0%
ROIC (TTM)	-1622.0%	-5277.0%
Financial Health
Cash	$140M	$25M
Debt	$582M	$0
Net Cash/Debt	$-442M	$25M
Current Ratio (TTM)	5.42x	4.82x
Quick Ratio (TTM)	2.74x	4.64x
Debt/Equity (TTM)	1.70x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.42	1.92
52W Performance	-28.6%	61.0%
YTD Performance	-43.6%	92.7%
% from 52W High	-49.8%	-62.0%
% from 52W Low	61.9%	117.8%
Efficiency & Yields
Asset Turnover (TTM)	0.59x	0.00x
FCF Yield (TTM)	9.7%	-68.2%
Earnings Yield (TTM)	-48.5%	-32.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	0.0
EV/GP/RG	0.27	N/A
Ticker research	View EBS research	View ZNTL research